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Abstract
Background: The risk of life-threatening complications, such as visceral disseminated varicella zoster virus (VZV)
infection, is greater in immunosuppressed individuals, such as systemic lupus erythematosus (SLE) patients.
Case presentation: Here, a case is reported of a Caucasian woman diagnosed with lupus nephritis and anti-phospholipid
syndrome, who was subjected to mycophenolate mofetil and high-dose steroid remission-induction therapy. Two months
later she developed abdominal pain followed by a fatal rapid multi-organ failure. As no typical skin rashes were evident,
death was initially attributed to catastrophic anti-phospholipid syndrome. However, autopsy and virological examinations on
archival material revealed a disseminated VZV infection.
Conclusions: Overall, this case highlights the importance of having a high clinical suspicion of fatal VZV infections in heavily
immunosuppressed SLE patients even when typical signs and symptoms are lacking.
Keywords: Varicella zoster virus, Herpesviruses, Systemic lupus erythematosus, Immunosuppression, Multiple
virus reactivations, Latent virus infections, Mycophenolate mofetil, Steroid therapy
Background
Varicella-zoster virus (VZV), a member of the family of
herpesviridae, remains latent in dorsal roots and auto-
nomic ganglia after a primary infection, but it can always
reactivate leading to a secondary infection, which is usu-
ally characterized by skin rash and acute neuritis. In
some cases, more severe complications may occur espe-
cially in immunocompromised patients, where multi-
organ involvement can develop with manifestations such
as encephalitis, aseptic meningitis, pneumonia and hepa-
titis [1].
Here, a case is reported of fatal visceral disseminated VZV
in a patient affected by systemic lupus erythematosus (SLE)
and anti-phospholipid syndrome (APS) treated with myco-
phenolate mofetil (MMF) and high-dose glucocorticoids.
Case presentation
A 49-year-old Caucasian woman affected by SLE and
APS presented to the Emergency Department complain-
ing of acute onset of abdominal pain. She denied fever,
nausea or vomit. Two months earlier, the patient, with
no previous medical history, had been hospitalized for
deep vein thrombosis. Her vaccination history was as
follows: diphtheria, polio, smallpox and tetanus; she had
never been vaccinated for chickenpox, measles, mumps
or rubella. During that period, she had been diagnosed
with both SLE —positive homogeneous antinuclear anti-
body titer of 1:320 with a homogeneous pattern— and
APS —positive lupus anticoagulant—, with multi-organ
dysfunction consisting of lupus nephritis with nephrotic
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syndrome, lung serositis, hemolytic anemia and arthritis.
Consequently, the patient had been treated with MMF
(1.5 g qd) and prednisone (50 mg qd) by nephrologists.
On hospital admission, vitals were normal except for
heart rate at 120 bpm. Physical examination revealed pe-
techiae at thorax and limbs. Complete blood count
showed low lymphocyte [0.50 × 109/L] and platelet (58 ×
109/L) counts. Other serum abnormal laboratory data in-
cluded decreased levels of immunoglobulin (Ig) G [118
mg/dL (NR:700–1600)] and increased values of aspartate
aminotransferase (AST), alanine aminotransferase (ALT)
[22x and 13x upper limit of normal (ULN), respectively]
and lactate dehydrogenase (LDH) [13x ULN]. Activated
partial thromboplastin time [1.5x ULN] and inter-
national normalized ratio (INR) [5.9] were prolonged,
whereas renal function was normal. At peripheral blood
smear, a number of echinocytes and 2–3 schistocytes/
high-power field were detected; platelets were normal-
sized but decreased (5/high-power field).
All these findings led to the suspicion of catastrophic
APS (CAPS). Therefore, methylprednisolone (1 g qd)
was started, but the patient’s conditions worsened dra-
matically as blood tests revealed persistent decrease in
platelet count [23 × 109/L] and substantial increase in
INR [7.75], LDH [25x ULN] and D-dimer [71x ULN],
consistent with a possible disseminated intravascular co-
agulation (DIC). Therefore, platelet transfusions and
fresh frozen plasma were administered. Later on,
plasmapheresis and immunoglobulin infusion became
necessary. The patient began to show signs of multiple
organ failure (MOF) such as acute kidney injury, increas-
ing elevation of liver function tests, glycemia and tropo-
nin I, appearance of confusion and, finally, respiratory
distress that required intubation. During the procedure,
pseudo-membranes, white exudates and diffuse pe-
techiae were detected in the pharynx (consistent with a
possible infective exudative pharyngitis). Later on,
hypotension and acute onset anemia appeared, and the
patient eventually died a few hours later.
At autopsy, diffuse skin petechiae were present. No
significant small vessel occlusions could be observed.
Pharyngeal mucosa showed ulcerative lesions associated
with cytopathic effects of the squamous epithelium (in-
cluding acantholysis, intranuclear inclusions and cyto-
plasmic vacuolization), which were suggestive of viral
infection (Fig. 1). The liver parenchyma contained areas
of coagulative and hemorrhagic necrosis, and hepatocyte
nuclei had a diffuse ground-glass appearance, suspicious
for viral inclusions. Moreover, occasional multinucleated
hepatocytes were observed (Fig. 2). No other significant
alterations were present. Being the morphological pic-
ture at pharyngeal and liver level consistent with herpes-
virus (HV) infection [2], immunohistochemistry was
performed with locally available antibodies [i.e. herpes
simplex virus 1 (HSV-1) and 2 (HSV-2) and cytomegalo-
virus (CMV)], but it resulted negative both in liver and
in pharynx.
In light of these findings and after a multidisciplinary
discussion of the case, it was opted to perform viro-
logical tests taking in due account the interpretative lim-
itations related to hypogammaglobulinemia and
quantitative real-time polymerase-chain reaction assays
(PCR; ELITe MGB Kits, ELITech, France) for HV on the
plasma samples that had been harvested on the day of
death. The most relevant data was a strong VZV positiv-
ity (19,600,000 copies/mL) in the absence of concomi-
tant immune activation [IgM index = 0.3 (cut-off > 1);
IgG < 10 mIU/mL (cut-off > 150)]. Furthermore, it was
found positivity for CMV [serological pattern of reacti-
vation with DNA at 3240 IU/ml], Epstein–Barr virus
(EBV) [serological pattern of reactivation with detectable
DNA below the lower limit of quantitation (LLQ) of
Fig. 1 Histological findings at autopsy. Pharyngeal mucosa showing acantholytic keratinocytes with intranuclear inclusions (hematoxylin-eosin
staining, magnification × 200)
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256 IU/mL] and human herpesvirus 6 (HHV-6) [DNA
below the LLQ of 350 IU/mL], whereas samples were
negative for HSV-1 and HSV-2 DNA (Fig. 3).
Discussion and conclusions
VZV infection may develop as a primary infection or re-
activation, the latter one being usually characterized by
skin rash and acute neuritis. Nevertheless, immunocom-
promised patients may display more severe and atypical
manifestations, such as encephalitis, aseptic meningitis,
pneumonia and hepatitis, along with disseminated vis-
ceral and cutaneous involvement [1]. These manifesta-
tions frequently represent a diagnostic challenge, as the
clinical picture might be insidious, leading to a difficulty
in the administration of a prompt and appropriate treat-
ment [3]. Therefore, it appears mandatory to take into
account unusual signs and symptoms, especially since
these subjects are at higher risk for the rare, but severe,
Fig. 2 Histological findings at autopsy. Hepatic parenchyma with foci of coagulative necrosis, multinucleated hepatocytes (center left and top
right) and ground-glass nuclei (hematoxylin-eosin staining, magnification × 200)
Fig. 3 Amplification curves of herpesviruses quantitative real-time polymerase-chain reaction assays. On the x-axis the cycle numbers are
represented. On the y-axis the fluorescence signals are reported on a logarithmic scale; Rn is the fluorescence of the reporter dye divided by the
fluorescence of the passive reference dye. Green lines represent the four internal controls. The other four curves represent the viral targets as
indicated in the Figure (i.e. VZV, CMV, EBV, and HHV-6). The horizontal central line is the threshold line
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disseminated VZV infection. Amongst immunosup-
pressed subjects, SLE patients have been demonstrated
to have a particularly high incidence of VZV infection
[4, 5]. However, the determinants of this positive associ-
ation have so far remained unclear, even though a lack
of cellular and/or humoral immunity, such as lymphope-
nia, may be playing a major role [6–8]. Another explan-
ation may be that the use of immunosuppressant drugs
is itself a risk factor for VZV. Indeed, the use of combin-
ation therapies consisting of MMF and high-dose gluco-
corticoids has been shown to increase VZV susceptibility
[9]. This aspect is particularly relevant to our case.
Nevertheless, it is noteworthy that, to be the best of our
knowledge, large studies examining the incidence of in-
fections in patients with rheumatic illness treated with
MMF are still lacking, so that generalizations can not yet
be made. Taking into account these limitations, only a
few studies suggest an increased incidence of infectious
diseases in such patients [10, 11], as MMF is generally
considered a safe drug compared to other immunosup-
pressive treatments, such as cyclophosphamide [12]. So,
even if a MMF role in facilitating viral infections is
strongly suspected, a regular monitoring of the presence
of VZV in rheumatic patients treated with MMF is not
yet recommended.
One of the most recent contributions from the Litera-
ture on this topic comes from Habuka et al. who recently
described a dramatic case of disseminated VZV infection
in a patient with lupus nephritis treated with the afore-
mentioned combination regimen, not only highlighting
again the possible harmful effect of immunosuppressive
drug therapy, but also suggesting a possible connection
between being Asian and experiencing worse outcomes
[13]. Although these elements make that case similar to
ours, here it is shown an unprecedented case in a Cauca-
sian subject. Moreover, our patient presented with a rarely
found combination of disseminated VZV infection and
MOF. Another peculiarity of our case is that the patient
did not show any signs or symptoms suggestive of VZV
infection, when this latter is usually accompanied by cuta-
neous manifestations, which help make a correct diagno-
sis. The only complaint reported by the patient was in fact
abdominal pain. This symptom is generally considered un-
common and it has always been reported as being con-
comitant with or, at least, preceding skin manifestations
[14]; it is generally considered to occur due to direct viral
infection of the enteric nervous system, from at least two
different pathways: viremia, in which circulating T cells
carry VZV, and axonal transport from dorsal root ganglia
[14, 15]. Coming back to our patient, it is possible that she
did not have the time to manifest typical skin signs. Not
surprisingly, the initial diagnosis failed to recognize viral
infection. The differential diagnosis was in fact between
acute DIC and CAPS. However, since a clear confirmation
of small vessel occlusion was lacking at autopsy, the final
cause of death was attributed to MOF secondary to severe
sepsis, the latter one being likely also the cause of the se-
vere progressive thrombocytopenia.
Another distinctive feature of this case is that, while
autopsy revealed signs of viral infection almost exclu-
sively in the pharynx and liver, blood PCR assays on
archival material showed an extremely high viral VZV
load. Unfortunately, it is not known how much time
went by from the first infection/reactivation to sample
collection. In any case, considering that the virological
tests were performed 3 weeks later, it is tempting to
speculate that there should have been an even higher
viral load at the collection time. Thus, VZV serology
seems to indicate a recent first infection to which the
patient was not able to react, probably due to a severe
immunosuppression state, as suggested by hypogamma-
globulinemia and lymphopenia (although, at least for the
latter one, viral infection cannot be excluded as a con-
tributory cause).
In this patient, the microbiological pattern was further
complicated by the occurrence of multiple HV infections
concomitant with VZV. These coreactivations are usu-
ally associated with poorer outcomes [16, 17]. Among
the most commonly reactivated HV, CMV and EBV and,
to a lesser extent, also HSV-1, HHV-6 and VZV have
been reported [18, 19]. Alternatively, reactivated HV can
directly transactivate other latent viruses. As an example,
it is known that HHV-6A can reactivate EBV through a
BamHI Z fragment leftward open reading frame (BZFL)-
1-dependent mechanism, or through the activation of
the Zebra promoter by a cyclic AMP-responsive element
[20, 21]. Thus, it is apparent that being able to differenti-
ate between clinically significant and latent viral burden
is of the utmost importance when dealing with immuno-
suppressed patients. In this regard, quantitative PCR as-
says can provide valuable help. In our patient, although
the CMV viral load was not as high as that of VZV, it
reached threshold values usually recommended for the
initiation of preemptive therapy. In contrast, EBV and
HHV-6 viremias were below the LLQ, so it was not pos-
sible to determine whether they corresponded to true la-
tent virus reactivations, as it was suggested by the
concomitant serological responses.
In conclusion, our investigation calls for increased
awareness about the unpredictable complications caused
by reactivations of specific latent infections under strong
immunosuppression: prompt clinical diagnosis might be
challenging, so early viral detection is highly recom-
mended [3]. This is because a high index of suspicion on
the part of the clinician to monitor for the presence of
VZV in MMF-treated patients could result in appropri-
ate timely treatment with acyclovir and better patient
outcomes.
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